Alivus Life Sciences submitted its Business Responsibility & Sustainability Report (BRSR) for the financial year ended March 31, 2026 (FY26), to the Bombay Stock Exchange and National Stock Exchange on August 11, 2026. The filing, made pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, reveals that exports accounted for 54.4% of the company’s total turnover. The report also highlights that the company voluntarily engaged the British Standards Institution (BSI) to provide independent limited assurance on its BRSR Core Key Performance Indicators (KPIs), enhancing transparency beyond the mandatory requirements outlined in SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2025/42 dated March 28, 2025.

The disclosures are presented on a standalone basis. Alivus Life Sciences reported a turnover of ₹25,518 Million and a net worth of ₹33,321 Million for the reporting period. The company’s paid-up capital stands at ₹245.47 Million. As an active pharmaceutical ingredient (API) manufacturer, the company serves more than 700 clients globally, including the top 20 generic pharmaceutical companies worldwide, across 75+ countries and 18+ states and union territories in India.

Operational and Environmental Metrics

The company operates four manufacturing plants and two offices nationally, with one manufacturing site at Chincholi currently under construction. In terms of environmental impact, total energy consumption increased to 8,27,182.57 Gigajoules (GJ) in FY26 from 7,92,079.40 GJ in FY25. This increase was driven by higher consumption from renewable sources, which rose to 5,13,253.72 GJ from 3,13,652.22 GJ, partly due to procured steam and bio-briquettes. Conversely, energy consumption from non-renewable sources decreased significantly to 3,13,928.85 GJ from 4,78,427.18 GJ.

Greenhouse gas (GHG) emissions showed notable reductions. Total Scope 1 emissions fell to 4,284.91 metric tonnes of CO2 equivalent from 7,232.78 metric tonnes in FY25. Scope 2 emissions dropped sharply to 58,030.65 metric tonnes from 88,035.94 metric tonnes, attributed to reduced consumption of purchased steam from coal. Total water discharged was 25,806.00 kilolitres, down from 27,830.84 kilolitres in the previous year.

Employee Well-being and Safety

Alivus employed 2,284 permanent employees and 1,666 workers at the end of FY26. The workforce composition included 92.43% male and 7.57% female employees. The company reported a permanent employee turnover rate of 21.63%, compared to 20.77% in FY25. Training coverage remained robust, with 100% of workers and 88.39% of employees receiving skill upgradation training.

Safety metrics indicated some incidents during the year. The Lost Time Injury Frequency Rate (LTIFR) per one million-person hours worked was 2.01 for employees and 1.70 for workers. There were nine recordable work-related injuries among employees and twelve among workers, including one fatality in each category. No high-consequence work-related injuries excluding fatalities were reported.

Governance and CSR Initiatives

The company’s Board of Directors oversees the implementation of Business Responsibility policies, supported by a dedicated ESG Committee. Independent evaluation of policy effectiveness was conducted by Dhir & Dhir Associates. Corporate Social Responsibility (CSR) activities focused on healthcare access through Project Sampurna, benefiting 1,89,258 individuals, and education via Project ViGyasa, reaching 23,705 students. Environmental sustainability efforts included planting 35,000 new trees and maintaining 46,500 existing plantations, contributing to carbon sequestration.

What the Numbers Show

The significant reduction in Scope 2 emissions, dropping by over 34%, contrasts with the overall increase in total energy consumption. This divergence indicates a strategic shift toward renewable energy sources, such as bio-briquettes and purchased green steam, rather than merely reducing energy use. While total energy demand rose, likely due to operational scale or process changes, the carbon intensity per rupee of turnover improved, reflecting successful decarbonization efforts aligned with the company’s target to become carbon neutral by 2030.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) reported a net profit of ₹5,645 million for the financial year ended March 31, 2026 (FY26), marking a 16% year-on-year increase from ₹4,857 million in FY25. The Mumbai-based active pharmaceutical ingredient (API) manufacturer delivered this growth despite the absence of Production Linked Incentive (PLI) benefits, which were withdrawn after FY24. The results underscore the effectiveness of its disciplined cost management and strategic shift towards higher-value, differentiated products.

Revenue from operations rose by 7% to ₹25,518 million in FY26, compared to ₹23,869 million in FY25. This top-line growth was primarily driven by a 13% expansion in its non-Glenmark Pharmaceuticals Limited (non-GPL) business, which now contributes 71% of overall revenues. The company also witnessed a meaningful recovery in its Contract Development and Manufacturing Organization (CDMO) segment, which recorded an 18% year-on-year growth as existing projects gained traction and newer initiatives scaled up.

The Board of Directors recommended a final dividend of ₹5 per equity share (face value ₹2 each), amounting to an outflow of approximately ₹613 million, subject to shareholder approval at the ensuing Annual General Meeting. Statutory auditors Walker Chandiok & Co LLP issued an unqualified opinion on the financial statements, confirming compliance with Indian Accounting Standards (Ind AS).

Financial Performance Highlights

The company’s operating efficiency improved significantly, with EBITDA rising by 20% to ₹8,577 million in FY26, up from ₹7,172 million in FY25. This expansion in operating profits allowed Alivus to achieve a record EBITDA margin of 33.6%, an improvement of 360 basis points from the previous year. Net profit margins also expanded to 22.1% from 20.4% in FY25.

Earnings per share (EPS) increased by 16% to ₹45.99 in FY26, compared to ₹39.63 in FY25. Total income, including other income, grew by 8% to ₹26,122 million. Employee benefits expenses rose by 8% to ₹2,725 million due to annual increments and headcount increases, while other expenses increased by 12% to ₹4,155 million, partly offset by a 3% decrease in utility charges.

What the Numbers Show

A critical observation from the FY26 results is the decoupling of profitability from government incentives. While revenue growth remained moderate at 7%, EBITDA expanded by 20%, indicating significant operational leverage. The company maintained its net debt-free status, with cash and cash equivalents standing at ₹7,824 million as of March 31, 2026, up from ₹5,487 million in FY25. This strong liquidity position supports its planned capital expenditure of approximately ₹540 crore for FY27, funded entirely through internal accruals, aimed at expanding manufacturing capacity at Solapur and establishing a new R&D center at Taloja.